Lansoprazole is an antituberculous prodrug targeting cytochrome bc 1

Nature Communications

Volumn 6, Issue , 2015, Pages

  Rybniker, Jan ^a,b   Vocat, Anthony ^a   Sala, Claudia ^a   Busso, Philippe ^a   Pojer, Florence ^a   Benjak, Andrej ^a   Cole, Stewart T ^a  

^a EPFL   (Switzerland)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; UBIQUINOL CYTOCHROME C REDUCTASE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; OMEPRAZOLE; PANTOPRAZOLE; PRODRUG; PROTON PUMP INHIBITOR; SULFIDE; TUBERCULOSTATIC AGENT;

BACTERIUM; BIOASSAY; CYTOCHROME; DRUG RESISTANCE; ENZYME ACTIVITY; IDENTIFICATION METHOD; INHIBITOR; METABOLISM; PATHOGEN; REACTION KINETICS; REDUCTION; TUBERCULOSIS;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG APPROVAL; DRUG SCREENING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; METABOLIC ACTIVATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG DEVELOPMENT; DRUG EFFECTS; FIBROBLAST; HIGH THROUGHPUT SCREENING; HUMAN; MACROPHAGE; METABOLISM; MOUSE; PROCEDURES;

MYCOBACTERIUM TUBERCULOSIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; ANTITUBERCULAR AGENTS; CELL LINE; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; ELECTRON TRANSPORT COMPLEX III; FIBROBLASTS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LANSOPRAZOLE; MACROPHAGES; MICE; MYCOBACTERIUM TUBERCULOSIS; OMEPRAZOLE; PRODRUGS; PROTON PUMP INHIBITORS; SULFIDES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84937013006     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8659     Document Type: Article

References (25)

1. Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12, 371-387 (2013).
2. World Health Organization. Global Tuberculosis Report 2014 (WHO, 2014) http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809-eng.pdf?ua=1.
3. Lechartier, B., Rybniker, J., Zumla, A. & Cole, S. T. Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol. Med. 6, 158-168 (2014).
4. Stanley, S. A. et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7, 1377-1384 (2012).
5. Brown, S. A., Palmer, K. L. & Whiteley, M. Revisiting the host as a growth medium. Nat. Rev. Microbiol. 6, 657-666 (2008).
6. Pethe, K. et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat. Commun. 1, 57 (2010).
7. Zumla, A., Nahid, P. & Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388-404 (2013).
8. Rybniker, J. et al. Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion. Cell Host Microbe 16, 538-548 (2014).
9. Welage, L. S. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy 23, 74S-80S (2003).
10. Reilly, J. P. Safety profile of the proton-pump inhibitors. Am. J. Health Syst. Pharm. 56, S11-S17 (1999).
11. Pearce, R. E., Rodrigues, A. D., Goldstein, J. A. & Parkinson, A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther. 277, 805-816 (1996).
12. Kubo, K., Oda, K., Kaneko, T., Satoh, H. & Nohara, A. Synthesis of 2-[[(4- fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1h-benzimidazoles as antiulcer agents. Chem. Pharm. Bull. 38, 2853-2858 (1990).
13. Pethe, K. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19, 1157-1160 (2013).
14. Abrahams, K. A. et al. Identification of novel imidazo[1, 2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS ONE 7, e52951 (2012).
15. Zhang, M. et al. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56, 5782-5789 (2012).
16. Arora, K. et al. Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58, 6962-6965 (2014).
17. Esser, L. et al. Inhibitor-complexed structures of the cytochrome bc1 from the photosynthetic bacterium Rhodobacter sphaeroides. J. Biol. Chem. 283, 2846-2857 (2008).
18. Birth, D., Kao, W. C. & Hunte, C. Structural analysis of atovaquone-inhibited cytochrome bc(1) complex reveals the molecular basis of antimalarial drug action. Nat. Commun. 5, 4029 (2014).
19. Derbyshire, E. R., Prudencio, M., Mota, M. M. & Clardy, J. Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. Proc. Natl Acad. Sci. USA 109, 8511-8516 (2012).
20. Rautio, J. et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7, 255-270 (2008).
21. Ballell, L. et al. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem 8, 313-321 (2013).
22. Lechartier, B., Hartkoorn, R. C. & Cole, S. T. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 5790-5793 (2012).
23. Makarov, V. et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol. Med. 6, 372-383 (2014).
24. Hartkoorn, R. C. et al. Towards a new tuberculosis drug: pyridomycin - nature's isoniazid. EMBO Mol. Med. 4, 1032-1042 (2012).
25. Rullas, J. et al. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob. Agents Chemother. 54, 2262-2264 (2010).